{
    "clinical_study": {
        "@rank": "64024", 
        "brief_summary": {
            "textblock": "RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow\n      to the tumor.\n\n      PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who\n      have metastatic neuroendocrine tumors."
        }, 
        "brief_title": "Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors", 
        "completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Gastrointestinal Carcinoid Tumor", 
            "Islet Cell Tumor", 
            "Lung Cancer", 
            "Neoplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoid Tumor", 
                "Lung Neoplasms", 
                "Neuroendocrine Tumors", 
                "Malignant Carcinoid Syndrome", 
                "Gastrointestinal Neoplasms", 
                "Adenoma, Islet Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the safety and efficacy of thalidomide in patients with metastatic low-grade\n           neuroendocrine tumors.\n\n      OUTLINE: Patients receive oral thalidomide once daily on weeks 1-8. Courses repeat every 8\n      weeks in the absence of disease progression or unacceptable toxicity.\n\n      PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed low-grade neuroendocrine tumors\n\n               -  Carcinoid tumors\n\n               -  Islet cell tumors\n\n          -  Metastatic disease\n\n          -  Progression of disease within past 4 weeks by radiological evidence\n\n          -  At least 1 bidimensionally measurable lesion by CT scan or MRI\n\n               -  Bone metastasis not considered measurable if only site of disease\n\n          -  No active brain metastases\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  Not specified\n\n        Performance status:\n\n          -  Karnofsky 70-100%\n\n        Life expectancy:\n\n          -  More than 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin normal\n\n          -  AST no greater than 2.5 times upper limit of normal (ULN)\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 times ULN OR\n\n          -  Creatinine clearance at least 50 mL/min\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Negative pregnancy test\n\n          -  Fertile patients must use 2 forms of effective contraception for 4 weeks before,\n             during, and for 4 weeks after study\n\n          -  No grade 2 or greater neuropathy\n\n          -  No other clinical circumstances that would preclude study\n\n          -  No other prior malignancy except:\n\n          -  Non-melanoma skin cancer\n\n          -  Other cancer that has been curatively treated, has had no evidence of recurrence\n             within the past 5 years, and is at low risk for recurrence\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  No prior thalidomide\n\n          -  No concurrent interferon\n\n        Chemotherapy:\n\n          -  No concurrent chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  At least 4 weeks since prior radiotherapy\n\n          -  No concurrent radiotherapy\n\n        Surgery:\n\n          -  At least 4 weeks since prior major surgery\n\n        Other:\n\n          -  No more than 1 prior systemic therapy regimen\n\n          -  At least 4 weeks since prior systemic therapy regimen\n\n          -  No other concurrent therapeutic agent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "December 7, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00027638", 
            "org_study_id": "MSKCC-01027", 
            "secondary_id": [
                "CDR0000069051", 
                "NCI-G01-2029"
            ]
        }, 
        "intervention": {
            "intervention_name": "thalidomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Thalidomide"
        }, 
        "keyword": [
            "metastatic gastrointestinal carcinoid tumor", 
            "recurrent gastrointestinal carcinoid tumor", 
            "gastrinoma", 
            "insulinoma", 
            "recurrent islet cell carcinoma", 
            "WDHA syndrome", 
            "somatostatinoma", 
            "pancreatic polypeptide tumor", 
            "glucagonoma", 
            "pulmonary carcinoid tumor"
        ], 
        "lastchanged_date": "June 17, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/MSKCC-01027"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10021"
                }, 
                "name": "Memorial Sloan-Kettering Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Trial Of Thalidomide In Patients With Low Grade Neuroendocrine Tumors (Carcinoid and Islet Cell Cancers)", 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Leonard B. Saltz, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00027638"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }, 
    "geocoordinates": {
        "Memorial Sloan-Kettering Cancer Center": "40.714 -74.006"
    }
}